布地奈德上市了吗？

Is it on the market? Budesonide was first developed and marketed by AstraZeneca Pharmaceutical Company in 1981. It was approved by the US FDA in August 2000. my country approved its import in November 2001, with specifications of 0.5mg/2ml and 1mg/2ml.

Budesonide suspension is an inhaled glucocorticoid that is administered through a nebulizer. It is a non-halogenated glucocorticoid. Inhaled budesonide suspension is used to treat bronchial asthma. It has local anti-inflammatory activity, high glucocorticoid receptor affinity, strong first-pass metabolism and a short half-life.

Depending on the nebulizer, the actual dose of budesonide inhaled by the patient is 40 to 60% of the labeled amount. The nebulization time and output dose depend on the flow rate, nebulizer volume and liquid volume.

Dosage of budesonide for children: aerosol inhalation, children aged 2 to 7 years old: 200 to 400 μg per day, divided into 2 to 4 times. Children over 7 years old: 200 to 800 μg per day, divided into 2 to 4 times. The maintenance dose should be reduced to the lowest dose and the symptoms can be controlled.

The dose of budesonide for adults: Adults: 200-1600 μg per day, divided into 2 to 4 times (for milder cases, 200-800 μg per day, for more severe cases, 800-1600 μg per day). Generally, 200 μg is taken once in the morning and evening, for a total of 400 μg a day; when the condition is severe, 200 mg is taken once, 4 times a day, for a total of 800 μg a day.

Aerosol or dry powder (Dubo, Pulmic) inhale 200 μg twice a day, or 400 μg once a day; for severe or refractory asthma, the dose can be increased to 400 μg to 800 μg each time, inhaled 1 to 2 times a day in the short term. After the condition is controlled, gradually reduce it to the above-mentioned usual dosage for maintenance. Budesonide treats rhinitis: 50 μg is sprayed into the nasal cavity twice a day.